CancerDrs

Ovarian Cancer clinical trials in Pennsylvania

80 actively recruiting ovarian cancer trials at 57 sites across Pennsylvania.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Pennsylvania:
  • Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
  • Saint Luke's Cancer Center - Allentown — Allentown, Pennsylvania
  • Saint Luke's University Hospital-Bethlehem Campus — Bethlehem, Pennsylvania
  • Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
  • Bryn Mawr Hospital — Bryn Mawr, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…

Sponsor: NRG Oncology
NCT ID: NCT06580314
Sites in Pennsylvania:
  • Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
  • Saint Luke's Cancer Center - Allentown — Allentown, Pennsylvania
  • Saint Luke's University Hospital-Bethlehem Campus — Bethlehem, Pennsylvania
  • Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
  • Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Pennsylvania:
  • Jefferson Abington Hospital — Abington, Pennsylvania
  • Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
  • Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
  • Geisinger Medical Center — Danville, Pennsylvania
  • Penn State Children's Hospital — Hershey, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part o…

Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Sites in Pennsylvania:
  • Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
  • Penn State Children's Hospital — Hershey, Pennsylvania
  • Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
  • Saint Christopher's Hospital for Children — Philadelphia, Pennsylvania
  • Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallo…

Sponsor: AbbVie
NCT ID: NCT05445778
Sites in Pennsylvania:
  • University Of Pittsburgh Medical Center Magee - Womens Hospital /ID# 269659 — Pittsburgh, Pennsylvania
  • Allegheny Health Network West Penn Hospital /ID# 269551 — Pittsburgh, Pennsylvania
  • Asplundh Cancer Pavilion /ID# 269574 — Willow Grove, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadj…

Sponsor: GOG Foundation
NCT ID: NCT05659381
Sites in Pennsylvania:
  • Jefferson Abington Hospital — Abington, Pennsylvania
  • Jefferson Hospital — Jefferson Hills, Pennsylvania
  • Forbes Hospital — Monroeville, Pennsylvania
  • West Penn Hospital — Pittsburgh, Pennsylvania
  • Wexford Hospital — Wexford, Pennsylvania
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.

Sponsor: Daiichi Sankyo
NCT ID: NCT06161025
Sites in Pennsylvania:
  • Perelman School of Medicine at the University of Pennsylvania — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Sites in Pennsylvania:
  • Asplundh Cancer Pavilion | Jefferson Health — Philadelphia, Pennsylvania
  • Allegheny Health Network — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice…

Sponsor: Genelux Corporation
NCT ID: NCT05281471
Sites in Pennsylvania:
  • AHN West Penn Hospital — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

Sponsor: Incyte Corporation
NCT ID: NCT07214779
Sites in Pennsylvania:
  • University of Pittsburgh Cancer Institute Cancer Services — Pittsburgh, Pennsylvania
  • Wellspan Gynecologic Oncology — York, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant…

Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04575935
Sites in Pennsylvania:
  • St. Luke's University Health Network — Bethlehem, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 pr…

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT07546500
Sites in Pennsylvania:
  • Site 0109 — Philadelphia, Pennsylvania
  • Site 0113 — Philadelphia, Pennsylvania
  • Site 0114 — Willow Grove, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

A Study of Intra-operative Imaging in Women With Ovarian Cancer

The purpose of this study is to find out whether using the PINPOINT imaging system intra-operatively can reduce the risk of anastomotic leaks and other complications after surgery for ovarian cancer, compared with standard intra-operative …

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT04878094
Sites in Pennsylvania:
  • Jefferson Abington Hospital — Willow Grove, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Pennsylvania:
  • Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
  • UPMC Altoona — Altoona, Pennsylvania
  • Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
  • Bryn Mawr Hospital — Bryn Mawr, Pennsylvania
  • Pocono Medical Center — East Stroudsburg, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite tre…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554328
Sites in Pennsylvania:
  • Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
  • UPMC Altoona — Altoona, Pennsylvania
  • Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
  • Bryn Mawr Hospital — Bryn Mawr, Pennsylvania
  • Pocono Medical Center — East Stroudsburg, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conduct…

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT05128825
Sites in Pennsylvania:
  • Site 0232 - University of Pennsylvania — Philadelphia, Pennsylvania
  • Site 0178 - Thomas Jefferson University — Philadelphia, Pennsylvania
  • Site 0277 - Alliance Cancer Specialist, PC — Wynnewood, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

Sponsor: Incyte Corporation
NCT ID: NCT07023627
Sites in Pennsylvania:
  • Penn State College of Medicine — Hershey, Pennsylvania
  • Asplundh Cancer Pavilion - Thomas Jefferson — Willow Grove, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…

Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Pennsylvania:
  • University of Pennsylvania / Abramson Cancer Center — Philadelphia, Pennsylvania
  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…

Sponsor: Genmab
NCT ID: NCT05579366
Sites in Pennsylvania:
  • USOR Alliance Cancer Specialist — Doylestown, Pennsylvania
  • Allegheny Health Network — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Pennsylvania:
  • Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania
  • University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
  • WellSpan York Cancer Center — York, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the sta…

Sponsor: Eli Lilly and Company
NCT ID: NCT04956640
Sites in Pennsylvania:
  • Fox Chase Cancer Center — Philadelphia, Pennsylvania
  • UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Pennsylvania:
  • Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
  • Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the st…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06787612
Sites in Pennsylvania:
  • University of Pittsburgh Medical Center, Magee-Womens Hospital — Pittsburgh, Pennsylvania
  • West Penn Hospital of Allegheny Health Network — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →

Showing 25 of 80 trials with sites in Pennsylvania. See all ovarian cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25